Musculoskeletal Cell Therapy

During the last 10 years, we have worked on the development of a somatic cell therapy in the field of muscle regeneration. So far, we successfully demonstrated the effect and safety of an allogeneic cell therapy approach in 20 patients in a Phase I/II study. This allogenic cell therapy is now further tested in a multi-centre Phase III trial to determine its efficacy, safety and tolerability in 240 patients. It is worldwide the first trial of its kind to treat muscle injuries.

Sie befinden sich hier:


  • Prof. Dr. Hans-Dieter Volk
    Institut für Medizinische Immunologie
  • Prof. Dr. Petra Reinke
    Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin
  • Prof. Dr. Gustav Steinhoff
    Referenz- und Translationszentrum für Stammzelltherapien Rostock

Industry Partners

  • Pluristem Therapeutics, Haifa, Israel
  • Heraeus Medical, Wehrheim, Germany